Fourth Quarter & Full Year 2022 Financial & Business Update

Strengthening our ADC Pipeline with Novel Targets Leveraging Validated Vedotin Technology Wave 1 Approved Vedotin ADCs Wave 2 Vedotin ADCs in Development & ADCETRIS® brentuximab vedotin | for injection PADCEV enfortumab vedotin-ejfv Injection for IV infusion 20 mg & 30 mg vials tivdak tisotumab vedotin-tftv for injection 40 mg POLIVY¹ polatuzumab vedotin-piiq INJECTION FOR INTRAVENOUS USE 30MG 140MG Disitamab Vedotin Ladiratuzumab Vedotin SGN-B6A SGN-B7H4V SGN-ALPV SGN-PDL1V SGN-STNV Seagen 1 Polivy is developed and commercialized by Roche which utilizes Seagen ADC technology 12

View entire presentation